By implementing ePASS, GlaxoSmithKline said it will be able to perform all of its global strategic sourcing processes online, including supplier qualification, RFx management, reverse auctions, and multi-stage, Internet-based negotiations. In addition, by using optimization-based decision support technology, Sourcing Group Managers across GlaxoSmithKline's business sectors will be able to analyze all purchasing scenarios using scientific algorithms to determine the optimal supply-base allocation. The ePASS solution is designed to combine auction, quoting, data management and decision support capabilities to lower purchased goods and service costs, improve supplier performance and achieve faster cycle times.
"Each business unit of GlaxoSmithKline has unique, complex decision factors that need to be taken into account when making sourcing decisions," said R. Gregg Brandyberry, Director Global Systems and Processes, GlaxoSmithKline Procurement. "We evaluated twelve sourcing solutions and chose ePASS because it was clearly the market leader in terms of the functionality required to take us to the next level in sourcing."
"We're on a mission to be the best procurement organization regardless of industry," commented Willie Deese, Senior Vice President, GlaxoSmithKline Procurement. "The breadth and depth of the Emptoris solution will allow us to bring more spend categories online quicker, thus driving a faster return on investment. In addition, ePASS was the only solution we evaluated that had true optimization-based decision support which will enable us to very quickly execute sophisticated bid analysis guaranteeing that we have the lowest total cost result."
"The pharmaceutical industry is yet another market that can greatly benefit from advanced e-sourcing solutions to enable the sourcing of complex goods and services online," said Avner Schneur, President and CEO of Emptoris. "GlaxoSmithKline has gained a reputation as a company that uses leading-edge technology to automate and optimize a number of its business processes. By implementing ePASS, GlaxoSmithKline will be able to substantially improve its bottom line by guaranteeing that it is maximizing cost savings in the area of supply-base allocation. GlaxoSmithKline's selection of Emptoris is more evidence that ePASS is the leading e-sourcing solution on the market today."
You can learn more about how strategic alliances and partnerships can increase your pipeline productivity at eyeforpharma's upcoming conference, Collaborative Strategies in R&D Europe, 2-4 December 2002, London.
For full event information click here or for more information on speaking or sponsorship, please contact Event Director, Sebastien Rooryck on Tel: +44 (0) 20 73 75 75 51 or Email: sebastien@eyeforpharma.com.
